Should I buy or sell 89bio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ETNB shares. View ETNB analyst ratings or view top-rated stocks .

What is 89bio's stock price target for 2024?

6 equities research analysts have issued 1 year price targets for 89bio's stock. Their ETNB share price targets range from $14.00 to $37.00. On average, they predict the company's share price to reach $28.83 in the next twelve months. This suggests a possible upside of 217.5% from the stock's current price. View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts .

How have ETNB shares performed in 2024?

89bio's stock was trading at $11.17 at the start of the year. Since then, ETNB shares have decreased by 18.7% and is now trading at $9.08. View the best growth stocks for 2024 here .

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ETNB earnings forecast .

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) issued its earnings results on Thursday, February, 29th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01.

What ETFs hold 89bio's stock?

ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS) and AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) . Harbor Health Care ETF (MEDI) .

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO) , Pfizer (PFE) , CVS Health (CVS) , RTX (RTX) , Alibaba Group (BABA) , Procter & Gamble (PG) , Sorrento Therapeutics (SRNE) , Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO) .

89bio (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are 89bio's major shareholders?

89bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bourgeon Capital Management LLC (0.04%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg , Kathleen Laporte, Michael R Hayden, Ollin B Sykes , Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd , Rohan Palekar and Ryan Martins . View institutional ownership trends .

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ETNB

89bio (ETNB) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free ETNB Stock Alerts

$9.08

+0.20 (+2.25%)

(As of 04/19/2024 ET)

Compare

Today's Range: $8.78
▼
$9.10
50-Day Range: $8.45
▼
$13.77
52-Week Range: $6.57
▼
$22.93

Volume: 1.01 million shs
Average Volume: 1.25 million shs
Market Capitalization: $848.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.83

Get 89bio alerts:

89bio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 217.5% Upside
$28.83 Price Target
Short Interest: Bearish
12.35% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$20.72 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.20) to ($2.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.19 out of 5 stars

Medical Sector

752nd out of 911 stocks

Pharmaceutical Preparations Industry

333rd out of 411 stocks

4.3

Analyst's Opinion

Consensus Rating
89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
89bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
12.35% of the outstanding shares of 89bio have been sold short.
Short Interest Ratio / Days to Cover
89bio has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in 89bio has recently increased by 3.96%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
89bio does not currently pay a dividend.
Dividend Growth
89bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ETNB.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for 89bio this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for ETNB on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 89bio insiders have bought 42,916.84% more of their company's stock than they have sold. Specifically, they have bought $20,722,500.00 in company stock and sold $48,173.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of 89bio is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for 89bio are expected to decrease in the coming year, from ($2.20) to ($2.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 89bio is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 89bio is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
89bio has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About 89bio Stock (NASDAQ:ETNB)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

ETNB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ETNB Stock News Headlines

April 17, 2024 | globenewswire.com

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

April 5, 2024 | globenewswire.com

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 3, 2024 | finance.yahoo.com

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

March 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for 89bio’s Pegozafermin: A Promising NASH Treatment with Strong Regulatory Endorsements

March 27, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)

March 27, 2024 | globenewswire.com

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

March 16, 2024 | finance.yahoo.com

ETNB Apr 2024 12.500 put

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 15, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)

March 12, 2024 | globenewswire.com

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

March 10, 2024 | 247wallst.com

Buffett Loads Up on This Stock Again, Plus CEO Insider Buying

March 8, 2024 | globenewswire.com

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 7, 2024 | msn.com

Insider Trading: Director Boosts Stake in 89bio (NASDAQ:ETNB) Stock

March 7, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for 89bio with Potential Market Edge in Fibrosis and Metabolic Diseases

March 6, 2024 | realmoney.thestreet.com

89bio price target raised by $8 at Evercore ISI, here's why

March 5, 2024 | globenewswire.com

89bio to Participate in the Leerink Partners Global Biopharma Conference

March 5, 2024 | wsj.com

89bio Inc.

March 5, 2024 | finance.yahoo.com

ETNB Mar 2024 20.000 put

March 5, 2024 | finance.yahoo.com

ETNB Mar 2024 20.000 call

March 2, 2024 | finance.yahoo.com

89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...

February 29, 2024 | globenewswire.com

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

February 24, 2024 | edition.cnn.com

89bio Inc

February 17, 2024 | ca.finance.yahoo.com

ETNB Mar 2024 15.000 call

February 17, 2024 | finance.yahoo.com

ETNB Mar 2024 7.500 put

February 6, 2024 | finance.yahoo.com

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024 | finanznachrichten.de

89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See More Headlines

Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ETNB
CUSIP: N/A
CIK: 1785173
Web: www.89bio.com
Phone: 415-432-9270
Fax: N/A
Employees: 70
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $28.83
High Stock Price Target: $37.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +222.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-142,190,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -31.01%
Return on Assets: -27.84%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 20.04
Quick Ratio: 20.04

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.75 per share
Price / Book: 1.55

Miscellaneous

Outstanding Shares: 93,500,000
Free Float: 89,387,000
Market Cap: $834.96 million
Optionable: Optionable
Beta: 1.04

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Rohan Palekar (Age 58)
CEO & Director
Comp: $990.52k
Mr. Quoc Le-Nguyen (Age 56)
Chief Technical Operations Officer & Head of Quality
Comp: $654.44k
Dr. Harry Mansbach M.D. (Age 59)
Chief Medical Officer
Comp: $691.87k
Mr. Ryan Stephen Martins (Age 45)
Chief Financial Officer
Mr. Shiva K. Natarajan CPA (Age 58)
Senior Vice President of Finance & Principal Accounting Officer
Ms. Annie J. Chang M.B.A.
VP of Investor Relations & Corporate Communications
Ms. Amanda Kurihara
Vice President of People & Culture
Ms. Yun Bai Ph.D.
VP and Head of Chemistry, Manufacturing & Controls ( CMC )
Ms. Melissa Abel
Senior Vice President of Commercial Strategy
Mr. Paul Shin
Senior Vice President of R&D Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ETNB Stock Analysis - Frequently Asked Questions

Should I buy or sell 89bio stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ETNB shares.
View ETNB analyst ratings or view top-rated stocks.
What is 89bio's stock price target for 2024?: 6 equities research analysts have issued 1 year price targets for 89bio's stock. Their ETNB share price targets range from $14.00 to $37.00. On average, they predict the company's share price to reach $28.83 in the next twelve months. This suggests a possible upside of 217.5% from the stock's current price.
View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts.
How have ETNB shares performed in 2024?: 89bio's stock was trading at $11.17 at the start of the year. Since then, ETNB shares have decreased by 18.7% and is now trading at $9.08.
View the best growth stocks for 2024 here.
When is 89bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ETNB earnings forecast.
How were 89bio's earnings last quarter?: 89bio, Inc. (NASDAQ:ETNB) issued its earnings results on Thursday, February, 29th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01.
What ETFs hold 89bio's stock?: ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS) and AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).Harbor Health Care ETF (MEDI).

What other stocks do shareholders of 89bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).
When did 89bio IPO?: 89bio (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.
Who are 89bio's major shareholders?: 89bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bourgeon Capital Management LLC (0.04%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends.
How do I buy shares of 89bio?: Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ETNB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

89bio (ETNB) Stock Price, News & Analysis

89bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About 89bio Stock (NASDAQ:ETNB)

ETNB Stock Price History

ETNB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ETNB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™